Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PI4KA | P42356 | 6/20 | 0.60 |
| ▸ | PI4K2B | Q8TCG2 | 6/20 | 0.60 |
| ▸ | PI4K2A | Q9BTU6 | 6/20 | 0.60 |
| ▸ | PI4KB | Q9UBF8 | 6/20 | 0.60 |
| ▸ | ADORA2A | P29274 | 5/20 | 0.37 |
| ▸ | ADORA1 | P30542 | 5/20 | 0.37 |
| ▸ | ADORA2B | P29275 | 2/20 | 0.37 |
| ▸ | YTHDC1 | Q96MU7 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
| ▸ | LMNA | P02545 | 1/20 | 0.30 |
| ▸ | SRC | P12931 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12141962 | 0.77 | ADORA1 (0.56) | PI4KAPI4K2BPI4K2API4KBADORA2A | |
| SCHEMBL14356547 | 0.77 | PI4KA (0.66) | PI4KAPI4K2BPI4K2API4KBADORA2A | |
| SCHEMBL22458549 | 0.76 | PI4KA (0.55) | PI4KAPI4K2BPI4K2API4KBADORA1 | |
| SCHEMBL22458518 | 0.76 | PI4KA (0.55) | PI4KAPI4K2BPI4K2API4KBADORA2A | |
| SCHEMBL19050172 | 0.75 | ADORA2A (0.39) | PI4KAPI4K2BPI4K2API4KBADORA2A | |
| SCHEMBL12141941 | 0.75 | ADORA2A (0.64) | PI4KAPI4K2BPI4K2API4KBADORA2A | |
| SCHEMBL9850316 | 0.75 | ADORA2A (0.42) | PI4KAPI4K2BPI4K2API4KBADORA2A | |
| SCHEMBL21126195 | 0.75 | PI4KA (0.64) | PI4KAPI4K2BPI4K2API4KBADORA2A | |
| SCHEMBL4569753 | 0.75 | PI4KA (0.64) | PI4KAPI4K2BPI4K2API4KBADORA2A | |
| SCHEMBL10248598 | 0.75 | PI4KA (0.64) | PI4KAPI4K2BPI4K2API4KBADORA2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230250089-A1 | MAP4K3 SMALL MOLECULE DRUG INHIBITORS AND METHODS OF USE THEREOF | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2023-08-10 | — | — | US | disclosed |
| US-20130165475-A1 | DEUTERIUM-ENRICHED HETEROCYCLIC COMPOUNDS AS KINASE INHIBITORS | ASCEPION PHARMACEUTICALS, INC. (CN) | 2013-06-27 | — | — | US | disclosed |
| US-20120122895-A1 | 5,6-BICYCLIC HETEROARYL-CONTAINING UREA COMPOUNDS AS KINASE INHIBITORS | JIANG, SHAN | 2012-05-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230250089-A1 | MAP4K3 SMALL MOLECULE DRUG INHIBITORS AND METHODS OF USE THEREOF | MAP4K3, MAP3K4, MAP3K3 | PI4KA 211/4885PI4K2B 269/4885PI4K2A 327/4885 |
| US-20120122895-A1 | 5,6-BICYCLIC HETEROARYL-CONTAINING UREA COMPOUNDS AS KINASE INHIBITORS | FLT3, CSF1R, EPHA2 | PI4KA 438/4885PI4K2B 488/4885PI4K2A 722/4885 |
| US-20130165475-A1 | DEUTERIUM-ENRICHED HETEROCYCLIC COMPOUNDS AS KINASE INHIBITORS | CDK2, CDK1, CDK3 | PI4KA 269/4885PI4K2B 360/4885PI4K2A 408/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.